Compare KLA Corp. (KLAC) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KLA Corp. vs McKesson Corporation — how do they compare? KLA Corp. trades at $217.58 (market cap $271.18B), while McKesson Corporation trades at $824.07 (market cap $97.35B). The key difference: KLA Corp. is far larger — about 2.8× McKesson Corporation's market cap, and KLA Corp. pays the higher dividend (0.44%). Which is the better fit depends on your goals.
| KLAC | MCK | |
|---|---|---|
Market Cap | $271.18B | $97.35B |
Sector | Technology | Health |
52-Week High | $301.71 | $995.69 |
52-Week Low | $84.39 | $659.01 |
Enterprise Value | $272.37B | $101.98B |
Dividend Yield | 0.44% | 0.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLA Corporation (KLAC) trades at $207.82, down 2.32% amid a semiconductor sector correction. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.94 versus $0.917 expected, and robust profitability with a 35.66% net margin. Technical indicators signal bearish momentum with key support at $200, while analyst consensus remains bullish with a $243.43 price target. Recent corporate actions include a 1:10 stock split effective June 12, 2026, and a $2.30 dividend paid June 2, 2026.
KLAC's outlook is supported by dominant market positioning in semiconductor process control and AI-driven demand, but high valuation multiples (P/E 60.25) and sector volatility present risks. The stock offers growth potential through semiconductor equipment expansion, though investors should monitor industry cyclicality and competitive pressures from peers like Applied Materials.
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
